Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026)
Invivyd's (IVVD) quarterly Liabilities and Shareholders Equity came in at $276.9 million in Q4 2025, up 113.78% YoY from $129.5 million in Q4 2024, and up 98.97% on a QoQ basis from $139.2 million in Q3 2025.
Invivyd (IVVD) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $276.9 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 113.78% year-over-year to $276.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $608.9 million (down 11.01% YoY) and the FY2025 annual result came in at $276.9 million, up 113.78% from the prior year.
- Liabilities and Shareholders Equity climbed to $276.9 million in Q4 2025, from $139.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $686.3 million in Q3 2021 to a low of $89.1 million in Q2 2025.
- A 5-year average of $316.7 million and a median of $276.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 428.27% — and 2025, when it plunged 51.85%.
- Tracing IVVD's Liabilities and Shareholders Equity over 5 years: stood at $620.1 million in 2021, then sank by 38.21% to $383.2 million in 2022, then plunged by 40.19% to $229.2 million in 2023, then sank by 43.49% to $129.5 million in 2024, then soared by 113.78% to $276.9 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $276.9 million (Q4 2025), $139.2 million (Q3 2025), and $89.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 218.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218.88 Mn |
| Dec 31, 2025 | 276.88 Mn |
| Sep 30, 2025 | 139.16 Mn |
| Jun 30, 2025 | 89.14 Mn |
| Mar 31, 2025 | 103.74 Mn |
| Dec 31, 2024 | 129.52 Mn |
| Sep 30, 2024 | 161.92 Mn |
| Jun 30, 2024 | 177.35 Mn |
| Mar 31, 2024 | 215.47 Mn |
| Dec 31, 2023 | 229.18 Mn |
| Sep 30, 2023 | 274.92 Mn |
| Jun 30, 2023 | 315.41 Mn |
| Mar 31, 2023 | 350.56 Mn |
| Dec 31, 2022 | 383.17 Mn |
| Sep 30, 2022 | 424.75 Mn |
| Jun 30, 2022 | 484.61 Mn |
| Mar 31, 2022 | 556.27 Mn |
| Dec 31, 2021 | 620.09 Mn |
| Sep 30, 2021 | 686.27 Mn |
| Jun 30, 2021 | 397.99 Mn |